POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

被引：1

作者：

Golan, T. ^{[1
]}

Hammel, P. ^{[2
]}

Reni, M. ^{[3
]}

Van Cutsem, E. ^{[4
]}

Mercade, T. Macarulla ^{[5
]}

Hall, M. J. ^{[6
]}

Park, J. O. ^{[7
]}

Hochhauser, D. ^{[8
]}

Arnold, D. ^{[9
]}

Oh, D-Y. ^{[10
]}

Reinacher-Schick, A. ^{[11
]}

Tortora, G. ^{[12
]}

Algul, H. ^{[13
]}

O'Reilly, E. M. ^{[14
]}

Bordia, S. ^{[15
]}

McGuinness, D. ^{[16
]}

Cui, K. Y. ^{[17
]}

Locker, G. ^{[18
]}

Kindler, H. ^{[19
]}

机构：

[1] Inst Oncol, Sheba Med Ctr, Oncol, Ramat Gan, Israel

[2] Hop Paul Brousse Assistance Publiquee Hopitaux Pa, Oncol, Villejuif, France

[3] Ist Sci San Raffaele, Med Oncol, IRCCS Osped, Milan, Italy

[4] Univ Hosp Gasthuisberg & KU Leuven, Digest Oncol, Leuven, Belgium

[5] Vall dHebron Univ Hosp, Med Oncol, Vall dHebron Inst Oncol, Barcelona, Spain

[6] Fox Chase Canc Ctr, Clin Genet, Philadelphia, PA USA

[7] Sungkyunkwan Univ, Samsung Med Ctr, Med Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] UCL Canc Inst, Oncol, Paul OGorman Bldg, London, England

[9] Asklepios Tumorzentrum Hamburg AK Altona, Oncol Haematol, Palliat Care, Hamburg, Germany

[10] Seoul Natl Univ Hosp, Canc Res Inst, Med, Seoul, South Korea

[11] Ruhr Univ Bochum, Hematol, Oncol & Palliat Care, St Josef Hosp, Bochum, Germany

[12] Fondazione Policlin Gemelli IRCCS, Med Oncol, Rome, Italy

[13] Comprehens Canc Ctr Munich TUM, Tech Univ, Internal Med 2, Klinikum Rechts Isar, Munich, Germany

[14] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[15] Merck Co Inc, Oncol Late Dev, Kenilworth, NJ USA

[16] Biometr & Informat Sci, Astrazeneca UK, Cambridge, England

[17] Late Dev Oncol, Oncol R, Astrazeneca US, Gaithersburg, MD USA

[18] GI Canc Drug Dev, Astrazeneca US Time Study, Gaithersburg, MD USA

[19] Univ Chicago, Med Sect Hematol Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.796

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1468P

引用

页码：S1086 / S1087

页数：2

共 50 条

[21] Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer
Kindler, Hedy L.
Yoo, Hyun Kyoo
Hettle, Robert
Cui, Karen Y. Y.
Joo, Seongjung
Locker, Gershon Y.
Golan, Talia
CANCER, 2023, 129 (09) : 1411 - 1418
[22] Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer phase III POLO trial
Golan, T.
Hammel, P.
Reni, M.
Van Cutsen, E.
Macarulla, T.
Hall, M.
Park, J.
Hochhauser, D.
Arnold, D.
Oh, D.
Reinacher-Shick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
McGuinness, D.
Cui, K.
Schlienger, K.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2019, 30
[23] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Golan, Talia
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui Karen
Schlienger, Katia
Locker, Gershon Y.
Kindler, Hedy L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[24] Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Wu, Bin
Shi, Lizheng
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (11): : 1528 - +
[25] POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
Golan, Talia
Oh, Do-Youn
Reni, Michele
Macarulla, Teresa Mercade
Tortora, Giampaolo
Hall, Michael J.
Reinacher-Schick, Anke C.
Borg, Christophe
Hochhauser, Daniel
Walter, Thomas
Hochster, Howard S.
Baker, Nigel
Locker, Gershon Y.
Kindler, Hedy L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] Olaparib as Maintenance Treatment Following First-line Platinum-based Chemotherapy (PBC) in Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer (mPC): Phase III POLO Trial
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D. Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Schlienger, K.
Locker, G. Y.
Kindler, H. L.
PANCREAS, 2019, 48 (10) : 1433 - 1434
[27] New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation
Hilmi, Marc
Neuzillet, Cindy
BULLETIN DU CANCER, 2020, 107 (10) : 961 - 962
[28] Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)
Reinacher-Schick, A.
Macarulla, T.
Kindler, H. L.
Hammel, P.
Reni, M.
Van Cutsem, E.
Hall, M. J.
Park, J-O
Hochhauser, D.
Arnold, D.
Oh, D-Y
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K.
Schlienger, K.
Locker, G. Y.
Golan, T.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 218 - 219
[29] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
Oh, D-Y.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, Oh
Hochhauser, D.
Arnold, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Schlienger, K.
Locker, G. Y.
Kindler, H. L.
ANNALS OF ONCOLOGY, 2019, 30
[30] POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).
Schwartz, Lawrence Howard
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen Mary
Fromageau, Jeremie
Ghiorghiu, Dana C.
McGuinness, David
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →